Prostate Cancer: Promising Biomarkers Related To Aggressive Disease [cáncer De Próstata: Biomarcadores Prometedores Relacionados Con La Enfermedad Agresiva]

dc.creatorRibeiro Da Silva M.N.
dc.creatorTobias-Machado M.
dc.creatorLima-Pompeo A.C.
dc.creatorReis L.O.
dc.creatorDa Silva Pinhal M.A.
dc.date2012
dc.date2015-06-26T20:29:27Z
dc.date2015-11-26T14:25:54Z
dc.date2015-06-26T20:29:27Z
dc.date2015-11-26T14:25:54Z
dc.date.accessioned2018-03-28T21:28:42Z
dc.date.available2018-03-28T21:28:42Z
dc.identifier
dc.identifierActas Urologicas Espanolas. , v. 36, n. 8, p. 484 - 490, 2012.
dc.identifier2104806
dc.identifier10.1016/j.acuro.2011.11.017
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-84865512818&partnerID=40&md5=38abe74366e59bd498c05d17a878144c
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/97039
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/97039
dc.identifier2-s2.0-84865512818
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1245899
dc.descriptionBackground: Although a rapidly growing number of candidate biological markers of prognosis and/or response to specific treatments in prostate cancer, none have to date showed ability to completely prognosticate prostate cancer on evidence based urology. Objective: To review the pertinent literature on the issue. Acquisition of evidence: A comprehensive review of the current literature was done focusing on promising biomarkers related to aggressive prostate cancer. Summary of evidence: Combined with the heterogeneous nature of the disease, mixt case series are the most common study design, impeding robust results and the development of an effective therapeutic strategy. Improvement in prostate cancer patient survival requires not only the identification of new therapeutic target based on detailed understanding of the biological mechanisms involved in metastatic dissemination and tumor growth but strong clinical studies as well. Conclusion: Better study design involving potential markers and including well-classified and staged patients with robust methodology and adequate outcomes (mainly survival) are necessary to the field evolution. © 2011 AEU. Published by Elsevier España, S.L. All rights reserved.
dc.description36
dc.description8
dc.description484
dc.description490
dc.descriptionJemal, A., Siegel, R., Xu, J., Ward, E., Cancer statistics: 2010 (2010) CA Cancer J Clin, 60, pp. 277-300
dc.descriptionReis, L.O., Old issues and new perspectives on prostate cancer hormonal therapy: The molecular substratum (2011) Med Oncol., , [Epub ahead of print]. DOI: 10.1007/s12032-011-9991-z
dc.descriptionPMID: 21626233
dc.descriptionFeldman, B.J., Feldman, D., The development of androgen-independent prostate cancer (2001) Nat Rev Cancer, 1, pp. 34-45
dc.descriptionGugliotta, A., Ferreira, U., Reis, L.O., Matheus, W.E., Denardi, F., Mamprim Stopiglia, R., Satisfaction analysis in men presenting with localized prostate cancer treated with radical prostatectomy or radiotherapy: Psychological and social aspects (2008) Actas Urol Esp, 32, pp. 411-416
dc.descriptionReis, L.O., Zani, E.L., Billis, A., Prudente, A., Denardi, F., Ferreira, U., The triple clinicopathologic features to seminal vesicle-sparing radical prostatectomy (2010) J Endourol, 24, pp. 1535-1539
dc.descriptionHernandez, J., Thompson, I.M., Prostate-specific antigen: A review of the validation of the most commonly used cancer biomarker (2004) Cancer, 101, pp. 894-904
dc.descriptionReis, L.O., Zani, E.L., Alonso, J.C., Simões, F.A., Rejowski, R.F., Ferreira, U., Does the criterion for prostate biopsy indication impact its accuracy? A prospective population-based outpatient clinical setting study (2011) Actas Urol Esp, 35, pp. 10-14
dc.descriptionNeto, A.S., Tobias-Machado, M., Wroclawski, M.L., Fonseca, F.L., Pompeo, A.C., Del Giglio, A., Molecular oncogenesis of prostate adenocarcinoma: Role of the human epidermal growth factor receptor 2 (HER-2/neu) (2010) Tumori, 96, pp. 645-649
dc.descriptionReis, L.O., Pereira, T.C., Lopes-Cendes, I., Ferreira, U., MicroRNAs: A new paradigm on molecular urological oncology (2010) Urology, 76, pp. 521-527
dc.descriptionHalvorsen, O.J., Høstmark, J., Haukaas, S., Høisaeter, P.A., Akslen, L.A., Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma (2000) Cancer, 88, pp. 416-424
dc.descriptionHenshall, S.M., Quinn, D.I., Lee, C.S., Head, D.R., Golovsky, D., Brenner, P.C., Altered expression of androgen receptor in the malignant epithelium and adjacent stroma is associated with early relapse in prostate cancer (2001) Cancer Res, 61, pp. 423-427
dc.descriptionRigaud, J., Tiguert, R., Decobert, M., Hovington, H., Latulippe, E., Laverdiere, J., Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy (2004) Prostate, 58, pp. 269-276
dc.descriptionCordon-Cardo, C., Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma (1998) J Natl Cancer Inst, 90, pp. 1284-1291
dc.descriptionFreedland, S.J., Degregorio, F., Sacoolidge, J.C., Elshimali, Y.I., Csathy, G.S., Dorey, F., Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy (2003) J Urol, 169, pp. 1325-1330
dc.descriptionKuczyk, M.A., Bokemeyer, C., Hartmann, J., Schubach, J., Walter, C., MacHtens, S., Predictive value of altered p27Kip1 and p21WAF/Cip1 protein expression for the clinical prognosis of patients with localized prostate cancer (2001) Oncol Rep, 8, pp. 1401-1407
dc.descriptionTsihlias, J., Kapusta, L.R., Deboer, G., Morava-Protzner, I., Zbieranowski, I., Bhattacharya, N., Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma (1998) Cancer Res, 58, pp. 542-548
dc.descriptionBerger, R., Lin, D.I., Nieto, M., Sicinska, E., Garraway, L.A., Adams, H., Androgen-dependent regulation of Her-2/neu in prostate cancer cells (2006) Cancer Res, 66, pp. 5723-5728
dc.descriptionNeto, A.S., Tobias-Machado, M., Wroclawski, M.L., Fonseca, F.L., Teixeira, G.K., Amarante, R.D., Her-2/neu expression in prostate adenocarcinoma: A systematic review and meta-analysis (2010) J Urol, 184, pp. 842-850
dc.descriptionBarba, J., Brugarolas, X., Tolosa, E., Rincón, A., Romero, L., Rosell, D., Time-influencing factors for biochemical progression following radical prostatectomy (2011) Actas Urol Esp, 35, pp. 201-207
dc.descriptionOxley, J.D., Winkler, M.H., Parry, K., Brewster, S., Abbott, C., Gillatt, D.A., P53 and bcl-2 immunohistochemistry in preoperative biopsies as predictors of biochemical recurrence after radical prostatectomy (2002) BJU Int, 89, pp. 27-32
dc.descriptionGrignon, D.J., Caplan, R., Sarkar, F.H., Lawton, C.A., Hammond, E.H., Pilepich, M.V., P53 status and prognosis of locally advanced prostatic adenocarcinoma: A study based on RTOG 8610 (1997) J Natl Cancer Inst, 89, pp. 158-165
dc.descriptionWu, T.T., Hsu, Y.S., Wang, J.S., Lee, Y.H., Huang, J.K., The role of p53: Bcl-2 and E-cadherin expression in predicting biochemical relapse for organ confined prostate cancer in Taiwan (2003) J Urol, 170, pp. 78-81
dc.descriptionKhor, L.Y., Moughan, J., Al-Saleem, T., Hammond, E.H., Venkatesan, V., Rosenthal, S.A., Bcl-2 and Bax expression predict prostate cancer outcome in men treated with androgen deprivation and radiotherapy on radiation therapy oncology group protocol 92-02 (2007) Clin Cancer Res, 13, pp. 3585-3590
dc.descriptionTobias-Machado, M., Fonseca, F., Fantinato, A.P., Bendit, I., Wroclawski, M.L., Cytokeratin 19 expression by reverse transcriptase-polymerase chain reaction in the peripheral blood of prostate cancer patients (2005) Tumori, 91, pp. 248-252
dc.descriptionFantinato, A.P., Tobias-Machado, M., Fonseca, F., Pinto, J.L., Wroclawski, M.L., Wroclawski, E., Her2/neu expression by reverse transcriptase-polymerase chain reaction in the peripheral blood of prostate cancer patients (2007) Tumori, 93, pp. 467-472
dc.descriptionLopergolo, A., Zaffaroni, N., Biomolecular markers of outcome prediction in prostate cancer (2009) Cancer, 115 (13 SUPPL.), pp. 3058-3067
dc.descriptionRosner, I.L., Ravindranath, L., Furusato, B., Chen, Y., Gao, C., Cullen, J., Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy (2007) Urology, 70, pp. 1225-1229
dc.descriptionShariat, S.F., Bensalah, K., Karam, J.A., Roehrborn, C.G., Gallina, A., Lotan, Y., Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer (2007) Clin Cancer Res, 13 (18 PART 1), pp. 5377-5384
dc.descriptionRhodes, D.R., Sanda, M.G., Otte, A.P., Chinnaiyan, A.M., Rubin, M.A., Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer (2003) J Natl Cancer Inst, 95, pp. 661-668
dc.descriptionGravdal, K., Halvorsen, O.J., Haukaas, S.A., Akslen, L.A., A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer (2007) Clin Cancer Res, 13, pp. 7003-7011
dc.descriptionNam, R.K., Sugar, L., Yang, W., Srivastava, S., Klotz, L.H., Yang, L.Y., Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer (2007) Br J Cancer, 97, pp. 1690-1695
dc.descriptionAttard, G., Clark, J., Ambroisine, L., Fisher, G., Kovacs, G., Flohr, P., Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer (2008) Oncogene, 27, pp. 253-263
dc.descriptionFernández-Serra, A., Rubio-Briones, J., García-Casado, Z., Solsona, E., López-Guerrero, J.A., Prostate cancer: The revolution of the fusion genes (2011) Actas Urol Esp, 35, pp. 420-428
dc.descriptionMehra, R., Tomlins, S.A., Shen, R., Nadeem, O., Wang, L., Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer (2007) Mod Pathol, 20, pp. 538-544
dc.descriptionBastian, P.J., Ellinger, J., Heukamp, L.C., Kahl, P., Müller, S.C., Von Rücker, A., Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy (2007) Eur Urol, 51, pp. 665-674
dc.descriptionEllinger, J., Bastian, P.J., Jurgan, T., Biermann, K., Kahl, P., Heukamp, L.C., CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer (2008) Urology, 71, pp. 161-167
dc.descriptionHenrique, R., Ribeiro, F.R., Fonseca, D., Hoque, M.O., Carvalho, A.L., Costa, V.L., High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients (2007) Clin Cancer Res, 13, pp. 6122-6129
dc.descriptionRosenbaum, E., Hoque, M.O., Cohen, Y., Zahurak, M., Eisenberger, M.A., Epstein, J.I., Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy (2005) Clin Cancer Res, 11, pp. 8321-8325
dc.descriptionAmundadottir, L.T., Sulem, P., Gudmundsson, J., Helgason, A., Baker, A., Agnarsson, B.A., A common variant associated with prostate cancer in European and African populations (2006) Nat Genet, 38, pp. 652-658
dc.descriptionEeles, R.A., Kote-Jarai, Z., Giles, G.G., Olama, A.A., Guy, M., Jugurnauth, S.K., Multiple newly identified loci associated with prostate cancer susceptibility (2008) Nat Genet, 40, pp. 316-321
dc.descriptionGudmundsson, J., Sulem, P., Manolescu, A., Amundadottir, L.T., Gudbjartsson, D., Helgason, A., Rafnar, T., Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24 (2007) Nat Genet, 39, pp. 631-637
dc.descriptionGudmundsson, J., Sulem, P., Steinthorsdottir, V., Bergthorsson, J.T., Thorleifsson, G., Manolescu, A., Two variants on chromosome 17 confer prostate cancer risk: And the one in TCF2 protects against type 2 diabetes (2007) Nat Genet, 39, pp. 977-983
dc.descriptionThomas, G., Jacobs, K.B., Yeager, M., Kraft, P., Wacholder, S., Orr, N., Multiple loci identified in a genome-wide association study of prostate cancer (2008) Nat Genet, 40, pp. 310-315
dc.descriptionYeager, M., Orr, N., Hayes, R.B., Jacobs, K.B., Kraft, P., Wacholder, S., Genome-wide association study of prostate cancer identifies a second risk locus at 8q24 (2007) Nat Genet, 39, pp. 645-649
dc.descriptionHelfand, B.T., Loeb, S., Meeks, J.J., Fought, A.J., Kan, D., Catalona, W.J., Pathological outcomes associated with the 17q prostate cancer risk variants (2009) J Urol, 181, pp. 2502-2507
dc.descriptionMorote, J., Del Amo, J., Borque, A., Ars, E., Hernández, C., Herranz, F., Improved prediction of biochemical recurrence after radical prostatectomy by genetic polymorphisms (2010) J Urol, 184, pp. 506-511
dc.descriptionAhn, J., Kibel, A.S., Park, J.Y., Rebbeck, T.R., Rennert, H., Stanford, J.L., Prostate Cancer Predisposition Loci and Risk of Metastatic Disease and Prostate Cancer Recurrence (2011) Clin Cancer Res, 17, pp. 1075-1081
dc.descriptionSun, T., Mary, L.G., Oh, W.K., Freedman, M.L., Pomerantz, M., Pienta, K.J., Inherited Variants in the Chemokine CCL2 Gene and Prostate Cancer Aggressiveness in a Caucasian Cohort (2011) Clin Cancer Res, 17, pp. 1546-1552
dc.descriptionBao, B.Y., Pao, J.B., Huang, C.N., Pu, Y.S., Chang, T.Y., Lan, Y.H., Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy (2011) Clin Cancer Res, 17, pp. 928-936
dc.descriptionPanteleakou, Z., Lembessis, P., Sourla, A., Pissimissis, N., Polyzos, A., Deliveliotis, C., Detection of circulating tumor cells in prostate cancer patients: Methodological pitfalls and clinical relevance (2009) Mol Med, 15, pp. 101-114
dc.descriptionOkegawa, T., Nutahara, K., Higashihara, E., Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer (2010) Int J Urol, 17, pp. 466-475
dc.descriptionMiller, M.C., Doyle, G.V., Terstappen, L.W., Significance of Circulating Tumor Cells Detected by the CellSearch System in Patients with Metastatic Breast Colorectal and Prostate Cancer (2010) J Oncol, 2010, p. 617421
dc.descriptionGoodman Jr., O.B., Fink, L.M., Symanowski, J.T., Wong, B., Grobaski, B., Pomerantz, D., Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors (2009) Cancer Epidemiol Biomarkers Prev, 18, pp. 1904-1913
dc.descriptionMarks, L.S., Fradet, Y., Deras, I.L., Blase, A., Mathis, J., Aubin, S.M., PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy (2007) Urology, 69, pp. 532-535
dc.descriptionDeras, I.L., Aubin, S.M., Blase, A., Day, J.R., Koo, S., Partin, A.W., PCA3: A molecular urine assay for predicting prostate biopsy outcome (2008) J Urol, 179, pp. 1587-1592
dc.descriptionWhitman, E.J., Groskopf, J., Ali, A., Chen, Y., Blase, A., Furusato, B., PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume (2008) J Urol, 180, pp. 1975-1978
dc.descriptionLiss, M.A., Santos, R., Osann, K., Lau, A., Ahlering, T.E., Ornstein, D.K., PCA3 molecular urine assay for prostate cancer: Association with pathologic features and impact of collection protocols (2010) World J Urol
dc.descriptionTosoian, J.J., Loeb, S., Kettermann, A., Landis, P., Elliot, D.J., Epstein, J.I., Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program (2010) J Urol, 183, pp. 534-538
dc.descriptionRubio-Briones, J., Fernández-Serra, A., Ramírez, M., Rubio, L., Collado, A., Casanova, J., Outcomes of Expanded Use of PCA3 Testing in a Spanish Population with Clinical Suspicion of Prostate Cancer (2011) Actas Urol Esp, 35, pp. 589-596
dc.descriptionReis, L.O., Vieira, L.F., Zani, E.L., Denardi, F., De Oliveira, L.C., Ferreira, U., Assessment of serum chromogranin-A as prognostic factor in high-risk prostate cancer (2010) J Investig Med, 58, pp. 957-960
dc.descriptionMa, Z., Tsuchiya, N., Yuasa, T., Huang, M., Obara, T., Narita, S., Clinical significance of polymorphism and expression of chromogranin-A and endothelin-1 in prostate cancer (2010) J Urol, 184, pp. 1182-1188
dc.descriptionKattan, M.W., Shariat, S.F., Andrews, B., Zhu, K., Canto, E., Matsumoto, K., The addition of interleukin-6 soluble receptor and transforming growth factor beta1 improves a preoperative nomogram for predicting biochemical progression in patients with clinically localized prostate cancer (2003) J Clin Oncol, 21, pp. 3573-3579
dc.descriptionShariat, S.F., Park, S., Trinh, Q.D., Roehrborn, C.G., Slawin, K.M., Karakiewicz, P.I., Plasminogen activation inhibitor-1 improves the predictive accuracy of prostate cancer nomograms (2007) J Urol, 178 (4 PART 1), pp. 1229-1236
dc.descriptionStephenson, A.J., Smith, A., Kattan, M.W., Satagopan, J., Reuter, V.E., Scardino, P.T., Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy (2005) Cancer, 104, pp. 290-298
dc.descriptionReis, L.O., Sasse, A.D., Matheus, W.E., Denardi, F., Stopiglia, R.M., Da Silva, M.M., Prostate cancer: Evidence based clinical practice (2009) Actas Urol Esp, 33, pp. 344-350
dc.descriptionGómez-Veiga, F., Alcaraz-Asensio, A., Burgos-Revilla, J., Cózar-Olmo, J.M., Advances in uro-oncology OncoForum: The best of 2010 (2011) Actas Urol Esp, 35, pp. 315-324
dc.languagees
dc.publisher
dc.relationActas Urologicas Espanolas
dc.rightsfechado
dc.sourceScopus
dc.titleProstate Cancer: Promising Biomarkers Related To Aggressive Disease [cáncer De Próstata: Biomarcadores Prometedores Relacionados Con La Enfermedad Agresiva]
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución